PDF(Pubmed)
Abstract：
BACKGROUND: We investigated the real-world efficacy of adjuvant therapy for stage I lung adenocarcinoma patients with pathological high-risk factors.
METHODS: Study participants were enrolled from November 1, 2016 and December 31, 2020. Clinical bias was balanced by propensity score matching. Disease-free survival (DFS) outcomes were compared by Kaplan-Meier analysis. The Cox proportional hazards regression was used to identify survival-associated factors. p ≤ 0.05 was the threshold for statistical significance.
RESULTS: A total of 454 patients, among whom 134 (29.5%) underwent adjuvant therapy, were enrolled in this study. One hundred and eighteen of the patients who underwent adjuvant therapy were well matched with non-treatment patients. Prognostic outcomes of the treatment group were significantly better than those of the non-treatment group, as revealed by Kaplan-Meier analysis after PSM. Differences in prevention of recurrence or metastasis between the targeted therapy and chemotherapy groups were insignificant. Adjuvant therapy was found to be positive prognostic factors, tumor size and solid growth patterns were negative.
CONCLUSIONS: Adjuvant therapy significantly improved the DFS for stage I lung adenocarcinoma patients with high-risk factors. Larger prospective clinical trials should be performed to verify our findings.
METHODS: Study participants were enrolled from November 1, 2016 and December 31, 2020. Clinical bias was balanced by propensity score matching. Disease-free survival (DFS) outcomes were compared by Kaplan-Meier analysis. The Cox proportional hazards regression was used to identify survival-associated factors. p ≤ 0.05 was the threshold for statistical significance.
RESULTS: A total of 454 patients, among whom 134 (29.5%) underwent adjuvant therapy, were enrolled in this study. One hundred and eighteen of the patients who underwent adjuvant therapy were well matched with non-treatment patients. Prognostic outcomes of the treatment group were significantly better than those of the non-treatment group, as revealed by Kaplan-Meier analysis after PSM. Differences in prevention of recurrence or metastasis between the targeted therapy and chemotherapy groups were insignificant. Adjuvant therapy was found to be positive prognostic factors, tumor size and solid growth patterns were negative.
CONCLUSIONS: Adjuvant therapy significantly improved the DFS for stage I lung adenocarcinoma patients with high-risk factors. Larger prospective clinical trials should be performed to verify our findings.
摘要：
背景：我们调查了具有病理高危因素的I期肺腺癌患者辅助治疗的真实世界疗效。
方法：研究参与者于2016年11月1日和2020年12月31日入组。通过倾向评分匹配来平衡临床偏倚。通过Kaplan-Meier分析比较无病生存（DFS）结果。Cox比例风险回归用于确定生存相关因素。p≤0.05为统计学意义的阈值。
结果：总共454名患者，其中134人(29.5%)接受了辅助治疗，参加了这项研究。接受辅助治疗的患者中有118例与非治疗患者非常匹配。治疗组的预后结果明显优于非治疗组，PSM后的Kaplan-Meier分析显示。靶向治疗组和化疗组在预防复发或转移方面差异不显著。发现辅助治疗是积极的预后因素，肿瘤大小和实体生长模式均为阴性.
结论：辅助治疗可显著改善具有高危因素的I期肺腺癌患者的DFS。应该进行更大的前瞻性临床试验来验证我们的发现。
方法：研究参与者于2016年11月1日和2020年12月31日入组。通过倾向评分匹配来平衡临床偏倚。通过Kaplan-Meier分析比较无病生存（DFS）结果。Cox比例风险回归用于确定生存相关因素。p≤0.05为统计学意义的阈值。
结果：总共454名患者，其中134人(29.5%)接受了辅助治疗，参加了这项研究。接受辅助治疗的患者中有118例与非治疗患者非常匹配。治疗组的预后结果明显优于非治疗组，PSM后的Kaplan-Meier分析显示。靶向治疗组和化疗组在预防复发或转移方面差异不显著。发现辅助治疗是积极的预后因素，肿瘤大小和实体生长模式均为阴性.
结论：辅助治疗可显著改善具有高危因素的I期肺腺癌患者的DFS。应该进行更大的前瞻性临床试验来验证我们的发现。
